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We prepared small unilamellar liposomes derivatised with single chain antibody fragments speciﬁc for the ED-B domain of B-
ﬁbronectin. This extracellular matrix associated protein is expressed around newly forming blood vessels in the vicinity of
many types of tumours. The single chain antibody fragments were functionalised by introduction of C-terminal cysteines and
linked to liposomes via maleimide groups located at the terminal ends of poly(ethylene glycol) modiﬁed phospholipids. The
properties of these anti-ED-B single chain antibody fragments-liposomes were analysed in vitro on ED-B ﬁbronectin expressing
Caco-2 cells and in vivo by studying their biodistribution and their therapeutic potential in mice bearing subcutanous F9
teratocarcinoma tumours. Radioactively labelled (
114mIndium) single chain antibody fragments-liposomes accumulated in the
tumours at 2–3-fold higher concentrations during the ﬁrst 2 h after i.v. injection compared to unmodiﬁed liposomes. After
6–24 h both liposome types were found in similar amounts (8–10% injected dose g
71) in the tumours. Animals treated i.v.
with single chain antibody fragments-liposomes containing the new cytotoxic agent 2'-deoxy-5-ﬂuorouridylyl-N
4-octadecyl-1-b-
D-arabinofuranosylcytosine (30 mg kg
-1 per dose, ﬁve times every 24 h) showed a reduction of tumour growth by 62–90%
determined on days 5 and 8, respectively, compared to animals receiving control liposomes. Histological analysis revealed a
marked reduction of F9 tumour cells and excessive deposition of ﬁbronectin in the extracellular matrix after treatment with
single chain antibody fragments-2-dioxy-5-ﬂuorouridylyl-N
4-octadecyl-1-b-D-arabinofuranosylcytosine-liposomes. Single chain
antibody fragments-liposomes targeted to ED-B ﬁbronectin positive tumours therefore represent a promising and versatile
novel drug delivery system for the treatment of tumours.
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Speciﬁc targeting of cytotoxic compounds to the tumour vascula-
ture and the surrounding stroma of growing tumours would
offer various advantages compared to conventional systemic
chemotherapy. Fibronectin (Fn), in particular the B-Fn isoform
with the ED-B oncofetal domain represents such a target protein
that is expressed in and around neoplastic blood vessels during
tumour growth and angiogenesis (Potts and Campbell, 1996;
Ruoslahti, 1999). ED-B Fn is produced by a variety of tumour
and endothelial cell lines and it was also found in a large number
of breast, prostate and colorectal carcinoma tissue samples of
mixed histotypes (Zardi et al, 1987; Kosmehl et al, 1996; Albrecht
et al, 1999; Midulla et al, 2000). Therefore, the ED-B isoform of Fn
represents a promising marker in growing solid tumours. Fn is an
extracellular adhesion glycoprotein that mediates interactions
between cells and extracellular matrix components. Fn polymorph-
ism originates from alternative splicing of the primary transcript of
a single gene in three regions.
Carnemolla characterised a single chain Fv antibody fragment
(scFv) binding to the human ED-B domain of the B-Fn isoform
using phage display technology (Carnemolla et al, 1996). Recently,
Neri and coworkers have prepared new anti-ED-B scFv with high
binding afﬁnity (Tarli et al, 1999; Viti et al, 1999) and a tissue
factor-ED-B-scFv fusion protein that mediated infarction of solid
tumours (Nilsson et al, 2001).
Liposomes are widely used as delivery systems with a broad spec-
trum of agents including chemotherapeutics, imaging agents,
antigens, lipids and DNA (Mastrobattista et al, 1999). Long-circu-
lating poly(ethylene) glycol (PEG) modiﬁed liposomes are used as
carriers for a variety of drugs (Cabanes et al, 1999). Targeting of
liposomes to sites of drug action is achieved by attachment of speci-
ﬁc antibodies or antibody fragments to their surface (Schwendener
et al, 1990; Hansen et al, 1995; de Kruif et al, 1996). In this work we
modiﬁed liposomes containing NH2-substituted PEG-chains with
the bifunctional reagent sulfosuccinimidyl-4-(N-maleimidomethyl)-
cyclohexane-1-carboxylate (sulfo-SMCC) for the introduction of
maleimide, allowing stable covalent S-C-linkage with C-terminal
cysteine modiﬁed anti-ED-B scFv (Marty et al, 2001).
Speciﬁc binding of the anti-ED-B-scFv-liposomes (scFv-lipo-
somes) was demonstrated on the ED-B expressing colorectal
carcinoma cell line Caco-2 (Pujuguet et al, 1996). The biodistribu-
tion of
114mIn-labelled liposomes was compared in mice bearing F9
teratocarcinoma tumours (Neri et al, 1997). Antitumour activity of
scFv-liposomes vs unmodiﬁed liposomes was shown by loading the
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s
Received 20 December 2001; revised 17 April 2002; accepted 23 April
2002
*Correspondence: R Schwendener; E-mail: reto.schwendener@psi.ch
British Journal of Cancer (2002) 87, 106–112
ã 2002 Cancer Research UK All rights reserved 0007–0920/02 $25.00
www.bjcancer.comliposomes with 2'-deoxy-5-ﬂuorouridylyl-N
4-octadecyl-1-b-D-
arabinofuranosylcytosine (5-FdU-NOAC), a new amphiphilic
compound with high cytotoxic activity (Cattaneo-Pangrazzi et al,
2000).
MATERIALS AND METHODS
Chemicals
Soy phosphatidylcholine (SPC) was obtained from L Meyer
(Hamburg, Germany). Cholesterol (CHOL) was purchased from
Fluka (Buchs, Switzerland). Methoxy-poly(ethylene glycol)-phos-
phatidylethanolamine (PE-PEG-OMet) was from Sygena (Liestal,
Switzerland). Amino-poly(ethylene glycol)-phosphatidylethanola-
mine (PE-PEG-NH2) was from Shearwater Polymers, Inc.
(Enschede, The Netherlands). 3,3'-dioctadecyloxacarbocyanine
perchlorate (DiO) and maleimide-BODIPY (4,4-diﬂuoro-1,3,5,7-
tetramethyl-4-bora-3a,4a-diaza-s-indacene-8-propionic acid) were
from Molecular Probes (Leiden, The Netherlands). 5-FdU-NOAC
was synthesised as described by Cattaneo-Pangrazzi et al (2000).
114mInCl3 was from NEN Life Science Products (Boston, MA,
USA) and [5-
3H]-N
4-octadecyl-1-b-D-arabinofuranosylcytosine
(5-
3[H]-NOAC) was custom labelled by Amersham Int. (Amer-
sham, UK). Sulfo-SMCC was from Pierce (Lausanne,
Switzerland). Dulbecco’s modiﬁed Eagles medium (DMEM), foetal
bovine serum and all medium supplements were from Gibco BRL
(Basel, Switzerland). All buffer salts and other chemicals were of
analytical grade and obtained from Fluka or Sigma (Buchs, Swit-
zerland).
Cell lines and animals
The human colon carcinoma cell line Caco-2 (H Wunderli-Allen-
spach, Swiss Federal Institute of Technology, Zurich, Switzerland)
was maintained in DMEM plus 10% heat-inactivated foetal bovine
serum, 1% L-glutamine, 1% nonessential amino acids, 1 mM
sodium pyruvate, 100 U ml
71 penicillin and 100 mgm l
71 strepto-
mycin. The human colon carcinoma cell line Co-115 (B Sordat,
Swiss Institute for Cancer Research, ISREC, Lausanne, Switzer-
land) and the murine F9 teratocarcinoma cell line (Neri et al,
1997) were maintained in DMEM as described above but without
nonessential amino acids and pyruvate. Female nude mice (CD-
15R4)-nu/nu were obtained from Charles River Wiga (Sulzfeld,
Germany) and kept in standard housing and normal diet at the
animal facility of the University Hospital Zurich. All animal
studies were performed under a license (Nr. 141/98) issued to
RA Schwendener by the Veterinary Department of the Canton
Zurich. The ethical guidelines that were followed meet the stan-
dards required by the UKCCCR guidelines (Workman et al,
1998).
Liposome preparation, modiﬁcation and labelling
The liposomes were composed of SPC:CHOL:PE-PEG-OMet
(unmodiﬁed liposomes) or PE-PEG-NH2 (scFv modiﬁed lipo-
somes) at a molar ratio of 1:0.2:0.07. For the in vitro binding
experiments liposomes were labelled with the lipophilic dye DiO
(0.004 mol parts referred to SPC). Maleimide-BODIPY was used
for the determination of the modiﬁcation efﬁciency of NH2-PEG-
PE. For therapeutic studies 5-FdU-NOAC (0.075 mol parts referred
to SPC) and 5-
3[H]-NOAC as trace label for the drug were added
to the lipid mixture.
All small unilamellar liposomes (SUV) were prepared by sequen-
tial ﬁlter extrusion of multilamellar liposomal preparations in
phosphate buffer (PB, 67 mM, pH 7.4) through Nuclepore
TM
membranes (Sterico, Dietikon, Switzerland) of 0.2 and 0.1 mm pore
diameter with a Lipex
TM extruder (Lipex Biomembranes Inc.,
Vancouver, Canada). Size and stability of the liposomes were
analysed with a particle sizer (Nicomp Model 370, Santa Barbara,
USA). For the biodistribution experiments liposomes containing
A23187 ionophore (0.001 mol parts referred to SPC) and nitrilo-
triacetic acid (1 mM) were labelled with
114mInCl3 as described
by Profﬁtt et al (1983). Brieﬂy,
114mInCl3 (7610
6 c.p.m. per
100 ml liposomes, 80 mg SPC ml
71) was incubated with unmodi-
ﬁed control liposomes for 30 min at 608C and with scFv-liposomes
for 2 h at RT. Free
114mIn
3+ was removed by size exclusion chro-
matography on a Sephadex G-50 column (Pharmacia, Uppsala,
Sweden).
114mIn entrapment was determined with a gamma coun-
ter (Cobra, Packard Instruments, Downers Grove, IL, USA).
Production and characterisation of anti-ED-B scFv
The scFv were constructed, produced, puriﬁed and characterised as
described elsewhere (Marty et al, 2001). Brieﬂy, the sequence of
anti-ED-B scFv (CGS-1) was modiﬁed by PCR using pDN351 as
a template (Neri et al, 1997) to functionalise the antibody by intro-
duction of additional cysteines at the C-terminal end, cloned into
the pPICZaA vector and transformed into Pichia pastoris. The
protein was produced by fermentation at medium-scale quantities
and puriﬁed in its dimeric form over an anion exchange column.
Preparation of scFv-liposomes
Liposomes containing 0.07 mol parts PE-PEG-NH2 referred to
SPC in PB were incubated with crystalline sulfo-SMCC at a molar
ratio of PEG-amino to maleimide groups of 1:5 for 30 min at
308C. Excess sulfo-SMCC was removed on a Biogel P6 column
(BioRad, Glattbrugg, Switzerland) in HBSE buffer (10 mM HEPES,
150 mM NaCl, 9.1 mM EDTA, pH 7.5). After reduction of the
scFv dimer (0.5 mg ml
71) in HBSE with a 2 mM ﬁnal concentra-
tion of tributylphosphine (TBP) for 4 h at 48C sulfo-SMCC
modiﬁed liposomes in HBSE were added and incubated for
20 h at 48C under an argon atmosphere. Modiﬁed liposomes
and non-reacted scFv were separated on a metrizamide gradient
by ultracentrifugation (7 h, 85000 g,4 8C, Schwendener et al,
1990). Liposome fractions were analysed by gel electrophoresis
for their protein content.
Binding of scFv-liposomes in vitro
Cover slips were placed into 12 well plates, coated with 100 ml
well
71 rat tail collagen-I (10 mg ml
71) and incubated for
30 min at 378C. Caco-2 and Co-115 cells (3610
5 cells well
71)
were plated and cultured for 48 h in a humidiﬁed 5% CO2 atmo-
sphere at 378C. Washed cells were incubated for 30 min at 48C
with 100 ml DiO labelled liposomes. Washed cover slips were
removed, treated with 10% glycerine in PB, placed on glass slides
and analysed on a ﬂuorescence microscope (Leica DLMB). As
negative controls the cells were incubated with unmodiﬁed ﬂuores-
cence labelled liposomes.
Biodistribution of
114mIn labelled scFv-liposomes in
tumour bearing mice
CD-15R4-nu/nu mice received 10
7 F9 cells per 50 ml PB s.c. on
both sides of the back. As tumours had reached sizes of 0.5–
1.0 cm in diameter, 200 ml
114mIn labelled liposomes containing
5 mg SPC and 37.5 mg scFv in PB were injected i.v. Five minutes,
1, 2, 6 and 24 h later the animals were anaesthetised, and sacriﬁced
by heart puncture and blood, heart, lung, liver, spleen, kidneys and
tumours were removed, weighed and the radioactivity measured by
gamma counting (Cobra, Packard Instruments). Blood correction
factors were applied to all organ samples (Allen et al, 1991). Statis-
tical parameters, the area under the curve (AUC) and half-lives of
the blood distribution curves (Figure 3A) were calculated with the
GraphPad Prism graphical software.
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F9 cells (10
7 per 50 ml PB) were injected s.c. on the abdominal side
of CD-15R4-nu/nu mice. Mice (5–10 per group) were treated
i.v. as the tumours had reached diameters of 6–8 mm with
scFv-5-FdU-NOAC-liposomes, 5-FdU-NOAC-liposomes, scFv-lipo-
somes, unmodiﬁed liposomes or scFv-dimers every 24 h for 5 days.
Each dose (0.2 ml) contained 0.6 mg 5-FdU-NOAC (30 mg kg
71
per dose) or corresponding amounts of lipids or protein. Tumour
growth was measured in a blinded fashion with a caliper every day
and volumes calculated using the following equation: V=p ab
2/6
(a=largest tumour diameter, b=perpendicular diameter). Tumour
vw
71 values were converted into percent change from baseline
using equation Vt6100/V0 (Vt=tumour volume at time t, V0=base-
line volume). Mice were sacriﬁced 8 days after onset of treatment
and tumours were dissected and weighed.
Histology
Samples of F9 tumours were collected 72 h after one treatment
(0.6 mg 5-FdU-NOAC) and histology was done as described by
Roscic-Mrkic et al (2001). Sections were incubated with anti-ED-
B Fn scFv L19 containing a FLAG tag (Viti et al, 1999), followed
by a FITC-labelled mouse anti FLAG M2 monoclonal antibody
(Sigma Chemical Co., St. Louis, MO, USA). FITC was detected
by sequential incubation with a rabbit anti-FITC antibody (Dako,
Glostrup, Denmark) and alkaline phosphatase (AP) and labelled
donkey antibodies against rabbit IgGs (Jackson Laboratories). AP
was visualised using naphthol AS-BI (6-bromo-2-hydroxy-3-napht-
holic acid-2-methoxy anilide) phosphate and new fuchsin (Sigma).
Sections were counterstained with hemalum.
RESULTS
Liposome preparation and scFv coupling
Total liposome numbers and the number of all lipophilic molecules
per liposome were calculated from the mean diameter obtained
from laser light scattering data and from liposome vesicle geometry
parameters as described by Huang and Mason (1978). An average
of 1670 accessible maleimide groups per liposome of 100 nm
diameter prepared with 0.07 mol PE-PEG-NH2 were calculated.
The efﬁciency of the modiﬁcation with sulfo-SMCC was deter-
mined by ﬂuorescence labelling of liposomes with maleimide-
BODIPY resulting in 60% of maleimide modiﬁed PEG-NH2-groups
(data not shown).
In the absence of reducing agents the anti-ED-B scFv constructs
form dimers due to disulﬁde bridge formation (data not shown;
Marty et al, 2001). Therefore, the disulﬁde bridges had to be
cleaved prior to coupling to maleimide modiﬁed liposomes. In
contrast to dithionite, that inactivated the binding properties of
the scFv (data not shown), reduction of the dimers with 2 mM
tributylphosphine for 4 h at 48C produced active and stable mono-
mers. Consequently, the scFv were coupled to the distal end of the
PEG chain via the cysteine thiol groups in the presence of the
reducing agent. Non-reacted scFv were separated from liposomes
on a metrizamide gradient. Fractions collected from the gradient
were analysed by gel electrophoresis, followed by Western blot
analysis (data not shown). Numbers of protein molecules linked
per liposome were calculated by determining the amount of lipid
based on DiO ﬂuorescence and the protein concentration. To lipo-
somes of 100+23 nm diameter an average of 220 scFv were
attached, corresponding to a coupling efﬁciency of 15+3%.
Binding of scFv-liposomes to ED-B positive cells in vitro
Caco-2 tumour cells cultured on collagen-I express ED-B Fn (Puju-
guet et al, 1996). The cells were incubated with DiO labelled scFv-
liposomes and binding was analysed by ﬂuorescence microscopy.
Fluorescence labelled scFv-liposomes bound strongly to ED-B Fn
positive Caco-2 cells (Figure 1B) but not to ED-B Fn negative
Co-115 control cells (Figure 1F). Unmodiﬁed liposomes did not
bind to Caco-2 cells (Figure 1D).
Biodistribution of scFv-liposomes in tumour bearing mice
For biodistribution studies we used F9 teratocarcinoma tumours
that strongly express ED-B Fn in vivo, are highly vascularised
and are not metastasising (Neri et al, 1997). Organ and tumour
distribution of the liposomes is shown in Table 1 and Figures 2
and 3. Figure 2 compares the accumulation of scFv- and unmodi-
ﬁed liposomes in tumours over a 24 h period. After 1 h the scFv-
liposomes were detectable at a higher level as compared to unmo-
diﬁed liposomes. Unmodiﬁed liposomes reached the level of scFv-
liposomes only after 6 h. The higher initial accumulation rate of
the scFv-liposomes may be due to speciﬁc binding of scFv to
ED-B Fn. After 6 h speciﬁc binding and penetration into the extra-
vascular space may be saturated. Extended circulation in the blood
of unmodiﬁed liposomes leads to comparable tumour accumula-
tion.
As shown in Table 1 unmodiﬁed liposomes had the known typi-
cal distribution characteristics of small pegylated liposomes. Two
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s Figure 1 Binding of anti-ED-B scFv-liposomes to cells cultured for 48 h on collagen-I coated cover slips: (A, C, E) Phase contrast images of the sections
shown in (B, D, F). ScFv-liposomes on ED-B positive Caco-2 cells (B) unmodiﬁed liposomes on ED-B positive Caco-2 cells (D) scFv-liposomes on ED-B
negative Co-115 cells (F). Detection of speciﬁc binding was demonstrated by labelling the liposomes with the lipophilic ﬂuorescent dye DiO. Magniﬁcation:
6400.
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liposomes were still detected in the blood, whereas only a small
fraction accumulated in the tumour (Figure 2, open bars). The
scFv-liposomes accumulated within 1 h at 50% ID in the liver
and at 11% ID in the spleen (Table 1). The rapid accumulation
in the spleen and the liver may be due to interactions between
the scFv and plasma proteins that accelerate liposome uptake in
the organs of the mononuclear phagocyte system (MPS, Harding
et al, 1997). Nevertheless, the circulation time of the scFv-lipo-
somes compared to a cytotoxic agent like free doxorubicin that
is cleared from blood within minutes is still notable. The control
liposomes had a half-life t1/2 of 3.7 h, whereas for the scFv-lipo-
somes a distribution half-life t1/2a of 52 min and an elimination
half-life t1/2b of 77 h were calculated (Figure 3A). The faster blood
clearance of scFv-liposomes resulted in a 2.5-fold lower AUC0–24 h
than unmodiﬁed liposomes (Figure 3A) and in a higher tumour to
blood ratio of 6.8 compared to 1.35 of unmodiﬁed liposomes 24 h
after administration (Figure 3B).
Therapy studies
Different cytotoxic agents (mitoxantrone, doxorubicin, NOAC and
5-FdU-NOAC) were tested on F9 cells using a cell viability test
(data not shown). The most active compound was mitoxantrone
(IC50=2.5 mM) followed by doxorubicin (IC50=10 mM) and 5-
FdU-NOAC (IC50=10 mM). We chose 5-FdU-NOAC because due
to its lipophilic properties this new duplex drug can be added
directly to the lipids during liposome preparation (Cattaneo-
Pangrazzi et al, 2000), whereas loading of liposomes with mitoxan-
trone or doxorubicin would necessitate additional preparation
steps. ScFv-5-FdU-NOAC-liposomes showed a remarkable reduc-
tion of tumour growth (Figure 4). After 5 days of treatment
tumour growth was inhibited by 62% (as calculated from the
tumour diameters) compared to control mice. Untreated mice
and the groups receiving control liposomes and scFv dimers
showed progressive tumour growth, whereas unmodiﬁed 5-FdU-
NOAC-liposomes had an intermediate anti-tumour effect. As
shown in Figure 4 treatment with 5-FdU-NOAC containing lipo-
somes was statistically signiﬁcantly different from empty
liposomes (P40.02) on days 5 to 8. However, the statistical
comparison between 5-FdU-NOAC liposomes and scFv-5-FdU-
NOAC liposomes revealed no signiﬁcant difference (P=0.14). After
8 days the tumours of untreated control mice had reached a large
size requiring the sacriﬁce of the animals. The tumours were
immediately excised and weighed. Calculated by weight a 90%
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Table 1 Biodistribution of scFv- and unmodiﬁed liposomes
Time (min) Blood Liver Kidney Spleen
scFv-liposomes (% ID+s.e.m.)
58 3 +15 22+15 1.0+0.1 3.7+1.2
60 24+65 0 +6.8 0.7+0.1 11+5.8
120 26+45 5 +4.4 0.8+0.1 11+0.6
360 14+35 7 +7.1 0.8+0.2 12+3.9
1440 2.4+0.6 57+2.9 1.8+0.2 10+1.8
Unmodiﬁed liposomes (% ID+s.e.m.)
58 6 +2.3 2.2+0.6 1.6+0.1 0.8+0.1
60 58+4.3 10+1.2 1.1+0.3 1.7+0.4
120 50+2.2 12+0.8 1.1+0.1 1.4+0.2
360 35+9.7 21+0.4 1.5+1.0 1.3+0.3
1440 10+2.1 33+7.4 2.5+0.3 2.5+0.3
Mice bearing s.c. F9 tumours (3/group) were injected with
114mIn labelled liposomes
and killed after the indicated time points. Results are expressed as % of injected radio-
activity per total organ (+s.e.m.). Lung and heart showed insigniﬁcant accumulation
of the liposomes (data not shown).
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Figure 2 Tumour accumulation of unmodiﬁed liposomes and scFv-lipo-
somes measured at different time points. Mice (three per group) bearing
s.c. F9 tumours were injected with
114mIn labelled liposomes and killed after
different time points. Results are expressed as % injected dose of radioac-
tivity per gram tissue (%ID g
71). Open bars, control liposomes; closed bars,
scFv-liposomes. At 1 and 2 h after injection the difference between the
two preparations was statistically signiﬁcant (*P50.05; +s.e.m.).
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Figure 3 Blood distribution curves (A) and tumour to blood ratios (B) of unmodiﬁed liposomes and scFv-liposomes. Mice (three per group) bearing s.c.
F9 tumours were injected i.v. with
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liposomes.
Histology
To obtain histology samples from F9 tumours we injected the same
liposome preparation intravenously into mice bearing tumours as
used in the therapy experiments. Using an anti CD31 antibody
no signiﬁcant differences in endothelial cell staining were observed
between all liposome preparations (data not shown). In contrast,
anti-ED-B-Fn staining showed distinct differences between
unloaded and 5-FdU-NOAC-liposomes (Figure 5). Empty unmodi-
ﬁed liposomes (Figure 5A) and empty scFv-liposomes (Figure 5B)
did not change tumour tissue morphology, whereas treatment with
unmodiﬁed liposomes containing the cytotoxic agent 5-FdU-
NOAC (Figure 5C) resulted not only in reduction of tumour size
(Figure 4), but also in a change of tissue morphology. These lipo-
somes had remarkable cytotoxic effects on tumour cells as shown
by the reduction of tumour cell number and loosened tissue archi-
tecture. At higher magniﬁcation apoptotic tumour cells were
frequently seen (data not shown). Treatment of mice with speciﬁc
scFv-5-FdU-NOAC-liposomes resulted in an excessive deposition
of Fn in the extracellular matrix (Figure 5D). Treatment with scFv
dimer did not alter tissue morphology (data not shown).
In summary, the 5-FdU-NOAC-liposome preparations had cyto-
toxic effects on tumour cells but not on tumour endothelial cells,
whereas the ED-B Fn speciﬁc scFv-5-FdU-NOAC liposomes caused
an intense deposition of Fn.
DISCUSSION
We prepared target speciﬁc immunoliposomes by attaching func-
tionalised scFv recognising the ED-B isoform of Fn to pegylated
liposomes. We used one of the most efﬁcient coupling methods
consisting of the conjugation of thiolated proteins to liposomes
containing either thiol or maleimide groups (Schwendener et al,
1990; Hansen et al, 1995). To prevent steric hindrance of antibo-
dies that are directly linked to the lipid surface of pegylated
liposomes we attached the scFv to the distal end of the PEG chains,
endowing them with higher antigen accessibility and more freedom
of motion. Thiol groups can easily be introduced into proteins
with bispeciﬁc coupling molecules such as N-succinimidyl-S-acet-
ylthioacetate (SATA) that interact with amino groups. However,
this chemical modiﬁcation may abolish the antibody binding prop-
erties as observed by modiﬁcation of the anti-ED-B scFv with
SATA (data not shown) and as reported by Uyama et al (1994).
Another disadvantage of introducing active groups randomly over
a protein is that the orientation of the protein molecules on the
liposome surface is not controllable. Thus, by introducing reactive
groups at a deﬁned site of the protein its orientation can be prede-
termined. To achieve this goal we used DNA-engineering for C-
terminal speciﬁc cysteine modiﬁcations of the scFv molecules. C-
terminal cysteine thiols offer a wide possibility for functionalisation
of the scFv molecules with the advantage of not interfering with
the antigen binding domain.
With such ﬂuorescently labelled scFv-liposomes we showed
strong binding in vitro on ED-B positive Caco-2 cells (Figure 1).
The biodistribution experiments resulted in an increased tumour
uptake of scFv-liposomes up to 2 h after administration (Figures
2 and 3B). At later time points unspeciﬁc pegylated liposomes
accumulated in comparable amounts (5–8 %ID g
71) in the
tumours. This may be explained by two observations, ﬁrstly the
well described high uptake of pegylated liposomes into solid
tumours that is mainly a consequence of the long blood circulation
times (Figure 3A). Secondly, scFv-liposomes were taken up by the
liver in high amounts with 50 %ID g
71 after 1 h (Table 1). This
reﬂects one of the most commonly recognised limitations for the
use of antibody modiﬁed liposomes in vivo. The rapid clearance
of scFv-liposomes from circulation is due to the opsonisation of
protein coated liposomes followed by the MPS uptake (Harding
et al, 1997). Thus, the numbers and the properties of protein mole-
cules linked to the liposome surface are of crucial importance
regarding their interactions with the MPS. As observed by others,
low numbers (510 per liposome) of scFv molecules lead to longer
blood circulation times and, consequently, to higher tumour
uptake (Goren et al, 1996; Park et al, 1997). As we used liposomes
that were coated with up to 220 scFv molecules these rather high
numbers of scFv might have contributed to the fast clearance
and high uptake into the liver and the spleen. Therefore, in future
experiments the number of scFv linked to a liposome will have to
be optimised. Reduced liposome binding to the target might also
be induced by repeated administration causing over saturation of
the Fn binding domains.
In the therapy studies the mice treated with speciﬁc scFv-5-FdU-
NOAC-liposomes showed a remarkable reduction in tumour size.
This enhanced cytotoxic effect of scFv-5-FdU-NOAC-liposomes
could be explained by the speciﬁc binding to ED-B Fn causing
longer lasting liposome retention in the tumour tissue and promot-
ing deeper penetration into the extracellular matrix. Nevertheless,
together with a reduction of the number of scFv molecules per
liposome, optimisation of the therapy schedule and the use of
other drugs might lead to improved therapeutic modalities.
The histological examination of the F9 tumours treated with 5-
FdU-NOAC containing liposomes revealed that the cytotoxic effect
mainly affected tumour cells. Examination of the Fn distribution in
the tumours by scFv L19 staining exposed a remarkable deposition
of Fn after treatment with the scFv-5-FdU-NOAC liposomes (Figure
5D) that was possibly responsible for inhibited tumour growth.
The cytotoxic activity of non-targeted 5-FdU-NOAC-liposomes
is noteworthy. 5-FdU-NOAC is a drug representative for a series
of new amphiphilic/lipophilic nucleoside duplex drugs that were
developed by us (Cattaneo-Pangrazzi et al, 2000). The chemical
combination of 5-FdU (ﬂoxuridine) with NOAC that is a lipophilic
derivative of cytosine arabinoside (Horber et al, 2000) to a new
heterodinucleoside dimer represents a new class of molecules with
high activity against solid tumours and excellent properties for
incorporation into liposomes. Target cell speciﬁc immunolipo-
somes offer the possibility to use the nucleoside duplex drugs
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Figure 4 In vivo effects of liposome treatment on F9 tumour growth. Tu-
mour bearing mice were treated ﬁve times every 24 h. Values represent
the mean+s.e.m. of 5–10 treated mice. The tumour volumes were calcu-
lated by equation V=pab
2/6 (a=largest tumour diameter, b=perpendicular
diameter). Tumour volume values were converted in % change from base-
line by equation Vt6100/V0 (Vt=volume at time t and V0=baseline vo-
lume). Statistical signiﬁcant difference was found between empty
liposomes and both 5-FdU-NOAC liposome preparations (* and #
P50.02; +s.e.m.).
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antrone) and with anti-angiogenic molecules that could
concomitantly be incorporated into the liposomes.
In conclusion, our experiments are the ﬁrst to our knowledge to
show inhibition of tumour growth by targeting immunoliposomes
to a protein that is not exclusively expressed on tumour cells but
also in the stroma and on endothelial cells of the tumour vascula-
ture. Keeping in mind that the ED-B domain of ﬁbronectin is
conserved between mouse and humans, ED-B Fn speciﬁc scFv-lipo-
somes containing cytotoxic and/or anti-angiogenic compounds
represent a promising approach for the therapeutic targeting of
solid tumours in humans.
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